The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient.
As part of the study, Biodesix is performing VeriStratR testing on eligible patients and serving as ALCMI's biorepository for all serum samples collected from CASTLE study subjects for future research. VeriStrat is a serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib.
